PFG
SRPT icon

PAX Financial Group’s Sarepta Therapeutics SRPT Stock Holding History

PAX Financial Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,818
Closed -$552K – 238
2023
Q2 		$552K Buy
4,818
+665
+16% +$85.8K 0.12% 150
2023
Q1 		$572K Buy
+4,153
New +$539K 0.14% 123

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

PAX Financial Group's SRPT Position: Q3 2023 in Review

PAX Financial Group sold out of Sarepta Therapeutics (SRPT) in Q3 2023, closing a stake of 4,818 shares — an estimated $552K sold.

PAX Financial Group first reported a position in SRPT in Q1 2023 and held it in 2 quarters. The position peaked at $572K in Q1 2023. 394 funds tracked by Wall St. Rank hold SRPT as of Q3 2023.

  • PAX Financial Group reported no remaining Sarepta Therapeutics position as of Q3 2023 after selling out during the quarter.
  • PAX Financial Group sold 4,818 Sarepta Therapeutics shares in Q3 2023, an estimated $552K.
  • PAX Financial Group first reported a position in Sarepta Therapeutics in Q1 2023 and held it in 2 quarters.
  • PAX Financial Group's Sarepta Therapeutics position peaked at $572K in Q1 2023.
  • 394 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2023.

Based on PAX Financial Group's 13F filing for Q3 2023, filed 13 Nov 2023.